Physician profile
Danielle Allen
NPI 1821322777
$2,461.25
in general payments reported to CMS, 2019-2025
27 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,184 · 2022: $546 · 2023: $344 · 2024: $271 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626 · Travel and Lodging: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.21 |
| Travel and Lodging | $104.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $607.69 | 2021-2023 | Bexsero, Arexvy |
| Novo Nordisk INC | $297.65 | 2021-2024 | |
| Abbvie INC. | $195.65 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $195.36 | 2021-2022 | |
| Nalu Medical, INC. | $137.98 | 2024 | Nalu Neurostimulation System |
| Lilly USA, LLC | $119.17 | 2021 | |
| Gilead Sciences, INC. | $116.15 | 2025 | |
| Abbott Laboratories | $104.85 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.93 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.67 | 2021-2022 | |
| Amgen INC. | $61.04 | 2021-2024 | Repatha, Otezla |
| Paratek Pharmaceuticals, INC. | $60.24 | 2021-2022 | |
| Stryker Corporation | $59.27 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $46.76 | 2021 | |
| Novartis Pharmaceuticals Corporation | $41.02 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.92 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $37.77 | 2021 | |
| Astellas Pharma US INC | $37.12 | 2021-2024 | Veozah |
| Radius Health, INC. | $30.94 | 2021 | |
| Vivus LLC | $22.30 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.06 | 2021 | |
| Eisai INC. | $21.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.03 | 2022 | |
| Merck Sharp & Dohme LLC | $16.46 | 2021 | |
| Pfizer INC. | $15.71 | 2021 | |
| Cranial Technologies, INC | $15.19 | 2021 | |
| Genentech USA, INC. | $7.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.